Strategies to develop chimerism in vascularized skin allografts across MHC barrier
✍ Scribed by Yavuz Demir; Selahattin Ozmen; Aleksandra Klimczak; Abir Lal Mukherjee; Maria Z. Siemionow
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 332 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0738-1085
No coin nor oath required. For personal study only.
✦ Synopsis
In this study, we investigated the effects of 7-day-protocols of ab-T-cell receptor monoclonal antibody (ab-TCRmAb), cyclosporine A (CsA), and tacrolimus (FK-506) immunosuppressive monotherapies, and their combinations on the survival of vascularized skin allografts (VSA). Forty-two transplantations of VSA across a strong MHC barrier were performed between ACI (RT1 a ) donors and Lewis (RT1 l ) recipients in seven groups. Isograft and allograft rejection controls received no treatment. Treatment groups received a 7-day protocol of ab-TCRmAb, CsA, or FK-506 monotherapy, or a combination of ab-TCRmAb/CsA and ab-TCRmAb/FK-506. VSA transplants were evaluated on a daily basis. Donor-specific chimerism was determined by flow cytometry (FC). The combined protocols of ab-TCRmAb/FK-506 and ab-TCRmAb/ CsA significantly prolonged VSA survivals compared to monotherapy groups (P < 0.005). FC analysis revealed 15.82% of donor-specific chimerism on day 7 under the ab-TCRmAb/CsA protocol and a gradual chimerism decline on day 63 posttransplant. The significant extension of VSA survival achieved under 7-day protocols of combined therapies was directly associated with the presence of donor-specific chimerism.